Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab
Open accessAbstract
To the Editor: Inhibition of immune checkpoints with the use of antibodies targeting programmed cell death 1 (PD-1) or monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has been used clinically in patients with various types of cancer. In the limited number of reported cases in which these antibodies have been used in patients who have undergone kidney transplantation,1 these agents have been associated with cell-mediated and antibody-mediated rejection (see Table S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). We report on a patient who received a renal transplant from a living related donor. . . .
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several transplant patients experienced a tumor response without rejection when their immunosuppressive regimen contained sirolimus.
“Interestingly, several transplant patients experienced a tumor response without rejection when their immunosuppressive regimen contained sirolimus.165,169,170”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [170]
Anecdotal use of mTOR inhibition as primary prevention was reported for patients with kidney transplants.
“For patients with kidney transplants, anecdotal use of mTOR inhibition (mTORi) as primary prevention was reported12,13.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [13]
Cites
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091 · see citing works
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · see citing works
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444 · see citing works
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J. D., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278 · see citing works
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,434 · see citing works
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Rincon, S. V. D., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 967 · see citing works
Post-Transplantation Lymphoproliferative Disorders in Adults
Dierickx, D., & Habermann, T. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1702693 · Cited by 488 · see citing works
Cutaneous Squamous Cell Carcinoma
Waldman, A., & Schmults, C. D. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.08.001 · Cited by 427 · see citing works
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294 · see citing works
Cancer in kidney transplant recipients
Au, E. H. K., Wong, G., & Chapman, J. R. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0022-6 · Cited by 271 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 203 · see citing works
Murakami, N., Mulvaney, P. M., Danesh, M. J., Abudayyeh, A., Diab, A. K., Abdel‐Wahab, N., Abdelrahim, M., Khairallah, P., Shirazian, S., Kukla, A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.12.015 · Cited by 195 · see citing works
Cutaneous squamous cell carcinoma
Que, S. K. T., Zwald, F. O., & Schmults, C. D. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.058 · Cited by 178 · see citing works
Yoest, J. M. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s126227 · Cited by 175 · see citing works
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Perazella, M. A., & Shirali, A. C. (2019) · Kidney International · doi:10.1016/j.kint.2019.07.022 · Cited by 173 · see citing works
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 162 · see citing works
DeLeon, T. T., Salomao, M. A., Aqel, B. A., Sonbol, M. B., Yokoda, R. T., Ali, A. H., Moss, A. A., Mathur, A. K., Chascsa, D. M., Rakela, J., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.07.05 · Cited by 157 · see citing works
Fisher, J., Zeitouni, N. C., Fan, W., & Samie, F. H. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.005 · Cited by 157 · see citing works
Kumar, V., Shinagare, A. B., Rennke, H. G., Ghai, S., Lorch, J. H., Ott, P. A., & Rahma, O. E. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0659 · Cited by 152 · see citing works
Immune Checkpoint Inhibitors in Organ Transplant Patients
Kittai, A. S., Oldham, H., Cetnar, J., & Taylor, M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000180 · Cited by 151 · see citing works
Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
Gassmann, D., Weiler, S., Mertens, J. C., Reiner, C. S., Vrugt, B., Nägeli, M., Mangana, J., Müllhaupt, B., Jenni, F., & Misselwitz, B. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000814 · Cited by 139 · see citing works
Friend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B. V., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. C. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135 · see citing works
Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C. C. H., Park, J., Spain, L. A., Turajlic, S., Ardolino, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.017 · Cited by 127 · see citing works
Stratigos, A., Dessinioti, C., Garbe, C., Lebbé, C., Amaral, T., Bataille, V. A., Dréno, B., Dummer, R., Fargnoli, M. C., Forsea, A., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113252 · Cited by 115 · see citing works
Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109 · see citing works
Garant, A., Guilbault, C., Ekmekjian, T., Greenwald, Z. R., Murgoi, P., & Vuong, T. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.009 · Cited by 108 · see citing works
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann, S. M., & Perazella, M. A. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.04.018 · Cited by 107 · see citing works
Use of checkpoint inhibitors in liver transplant recipients
Munker, S., & Toni, E. N. D. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618774631 · Cited by 104 · see citing works
Abbas, F., Kossi, M. E., Shaheen, I. S., Sharma, A. K., & Halawa, A. M. (2020) · World Journal of Transplantation · doi:10.5500/wjt.v10.i2.29 · Cited by 100 · see citing works
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020
Gupta, S., Cortazar, F. B., Riella, L. V., & Leaf, D. E. (2020) · Kidney360 · doi:10.34067/kid.0000852019 · Cited by 96 · see citing works
Jennings, J. J., Mandaliya, R. H., Nakshabandi, A., & Lewis, J. H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1574744 · Cited by 93 · see citing works
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review
Portuguese, A. J., Tykodi, S. S., Blosser, C. D., Gooley, T., Thompson, J. A., & Hall, E. T. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7009 · Cited by 85 · see citing works
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Hanna, G. J., Dharaneeswaran, H., Giobbie‐Hurder, A., Harran, J., Liao, Z., Pai, L. H., Tchekmedyian, V., Ruiz, E. S., Waldman, A. H., Schmults, C. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01498 · Cited by 80 · see citing works
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79 · see citing works
An update on cancer after kidney transplantation
Cheung, C. Y., & Tang, S. C. W. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy262 · Cited by 78 · see citing works
Tsung, I., Worden, F. P., & Fontana, R. J. (2020) · The Oncologist · doi:10.1002/onco.13539 · Cited by 75 · see citing works
Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma
Varkaris, A. S., Lewis, D. W., & Nugent, F. W. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.387 · Cited by 75 · see citing works
Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients
Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Markovic, S. N., & Herrmann, S. M. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.11.015 · Cited by 74 · see citing works
Aguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68 · see citing works
Kuo, J. C.-Y., Lilly, L., & Hogg, D. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000410 · Cited by 65 · see citing works
Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient
Biondani, P., Martin, E. D., & Samuel, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx548 · Cited by 60 · see citing works
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67 · see citing works
Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma
Claveau, J., Archambault, J., Ernst, D. S., Giacomantonio, C. A., Limacher, J. J., Murray, C. S., Parent, F., & Zloty, D. M. (2020) · Current Oncology · doi:10.3747/co.27.6015 · Cited by 51 · see citing works
Kitchlu, A., Jhaveri, K. D., Sprangers, B., Yanagita, M., & Wanchoo, R. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab090 · Cited by 47 · see citing works
Abdelrahim, M., Esmail, A., Saharia, A., Abudayyeh, A., Abdel‐Wahab, N., Diab, A. K., Murakami, N., Kaseb, A. O., Chang, J. C., Gaber, A. O., et al. (2022) · Cancers · doi:10.3390/cancers14071760 · Cited by 47 · see citing works
Miller, D. M., Faulkner-Jones, B. E., Stone, J. R., & Drews, R. E. (2017) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.06.005 · Cited by 46 · see citing works
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Zehou, O., Leibler, C., Arnault, J., Sayegh, J., Montaudié, H., Rémy, P., Glotz, D., Cordonnier, C., Martin, L., & Lebbé, C. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15071 · Cited by 45 · see citing works
Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients
Venkatachalam, K., Malone, A. F., Heady, B., Santos, R. D., & Alhamad, T. (2019) · Transplantation · doi:10.1097/tp.0000000000002914 · Cited by 44 · see citing works
Immunotherapy use outside clinical trial populations: never say never?
Rzeniewicz, K., Larkin, J., Menzies, A. M., & Turajlic, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.199 · Cited by 42 · see citing works
Lai, H.-C., Lin, J., Hwang, T. I. S., Liu, Y., Yang, A., & Wu, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092194 · Cited by 41 · see citing works
Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment
Hurkmans, D. P., Verhoeven, J. G. H. P., de Leur, K., Boer, K., Joosse, A., Baan, C. C., von der Thüsen, J. H., van Schaik, R. H. N., Mathijssen, R. H. J., van der Veldt, A. A. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0653-6 · Cited by 41 · see citing works
T-cell Exhaustion in Organ Transplantation
Angeletti, A., Cantarelli, C., Riella, L. V., Fribourg, M., & Cravedi, P. (2021) · Transplantation · doi:10.1097/tp.0000000000003851 · Cited by 38 · see citing works
Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
Kawashima, S., Joachim, K., Abdelrahim, M., Abudayyeh, A., Jhaveri, K. D., & Murakami, N. (2022) · Korean Journal of Transplantation · doi:10.4285/kjt.22.0013 · Cited by 39 · see citing works
PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report
Goldman, J. W., Abdalla, B. A., Mendenhall, M. A., Sisk, A. E. J., Hunt, J., Danovitch, G. M., & Lum, E. L. (2018) · BMC Nephrology · doi:10.1186/s12882-018-1003-5 · Cited by 37 · see citing works
Cutaneous squamous cell carcinoma in the organ transplant recipient
Bibee, K., Swartz, A., Sridharan, S., Kürten, C. H. L., Wessel, C. B., Skinner, H. D., & Zandberg, D. P. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104562 · Cited by 37 · see citing works
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 40 · see citing works
Winkler, J. K., Gutzmer, R., Bender, C., Lang, N., Zeier, M. G., Enk, A., & Hassel, J. C. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000188 · Cited by 35 · see citing works
Delyon, J., Zuber, J., Dorent, R., Poujol‐Robert, A., Péraldi, M., Anglicheau, D., & Lebbé, C. (2020) · Transplantation · doi:10.1097/tp.0000000000003292 · Cited by 34 · see citing works
Londoño, M., Reig, M., & on behalf of the RETOINMUNO Multidisciplinary Group (2020) · Cancers · doi:10.3390/cancers12113446 · Cited by 34 · see citing works
Immune checkpoint blockade for organ-transplant recipients with cancer: A review
Rünger, A., Schadendorf, D., Hauschild, A., & Gebhardt, C. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.010 · Cited by 34 · see citing works
Ferrándiz‐Pulido, C., Leiter, U., Harwood, C. A., Proby, C. M., Guthoff, M., Scheel, C., Westhoff, T. H., Bavinck, J. N. B., Meyer, T., Nägeli, M., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004459 · Cited by 33 · see citing works
Deltombe, C., Garandeau, C., Renaudin, K., & Hourmant, M. (2017) · Transplantation · doi:10.1097/tp.0000000000001861 · Cited by 32 · see citing works
Wu, C., Juang, G.-D., & Lai, H.-C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx409 · Cited by 30 · see citing works
Rienzo, M., Skirecki, T., Monneret, G., & Timsit, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2102477 · Cited by 28 · see citing works
Danesh, M. J., Mulvaney, P. M., Murakami, N., Riella, L. V., Silk, A. W., Hanna, G. J., & Schmults, C. D. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02644-2 · Cited by 27 · see citing works
Trager, M. H., Coley, S. M., Dube, G. K., Khan, S. A., Ingham, M. A., Samie, F. H., Geskin, L. J., McDonnell, D. E., Brouder, D., Saenger, Y. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000908 · Cited by 27 · see citing works
Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant
Wanchoo, R., Riella, L. V., Uppal, N. N., Lopez, C. A., Nair, V. V., Devoe, C., & Jhaveri, K. D. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000006 · Cited by 26 · see citing works
The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders
Marcelis, L., & Tousseyn, T. (2019) · Cancer Microenvironment · doi:10.1007/s12307-018-00219-5 · Cited by 26 · see citing works
Shim, Y. J., Khedraki, R., Dhar, J., Fan, R., Dvorina, N., Valujskikh, A., Fairchild, R. L., & Baldwin, W. M. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.037 · Cited by 25 · see citing works
Qiu, J., Tang, W., & Du, C. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200520084415 · Cited by 24 · see citing works
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Smedman, T. M., Line, P., Guren, T. K., & Dueland, S. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1479069 · Cited by 24 · see citing works
Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0004 · Cited by 24 · see citing works
Sadaat, M., & Jang, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.2017.027326 · Cited by 23 · see citing works
Acute Kidney Injury in Cancer Immunotherapy Recipients
Joseph, A., Lafarge, A., Azoulay, É., & Zafrani, L. (2022) · Cells · doi:10.3390/cells11243991 · Cited by 23 · see citing works
Singh, P., Visger, J. R. V., Prosek, J. M., Rovin, B. H., Pesavento, T. E., Olencki, T. E., & Pandey, D. (2018) · Transplantation · doi:10.1097/tp.0000000000002502 · Cited by 21 · see citing works
Meerhaeghe, T. V., Murakami, N., Moine, A. L., Brouard, S., Sprangers, B., & Degauque, N. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae061 · Cited by 20 · see citing works
Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
Bermejo, S., Bolufer, M., Riveiro‐Barciela, M., & Soler, M. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906565 · Cited by 18 · see citing works
Maggiore, U., Palmisano, A., Buti, S., Giudice, G. C., Cattaneo, D., Giuliani, N., Fiaccadori, E., Gandolfini, I., & Cravedi, P. (2021) · Transplant International · doi:10.1111/tri.14115 · Cited by 17 · see citing works
Transplant Onconephrology in Patients With Kidney Transplants
Murakami, N., Webber, A. B., & Nair, V. V. (2022) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.002 · Cited by 17 · see citing works
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16 · see citing works
Kidney Toxicities Associated With Novel Cancer Therapies
Lefebvre, J., & Glezerman, I. G. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.05.006 · Cited by 17 · see citing works
Khaddour, K., Murakami, N., Ruiz, E. S., & Silk, A. W. (2024) · Cancers · doi:10.3390/cancers16173083 · Cited by 16 · see citing works
Babey, H., Quéré, G., Descourt, R., Calloch, R. L., Lanfranco, L., Nousbaum, J., Cornec, D., Tison, A., & CHOUAID, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1499468 · Cited by 16 · see citing works
Onconephrology 2022: An Update
Bonilla, M. A., Gudsoorkar, P. S., Wanchoo, R., Herrmann, S. M., & Jhaveri, K. D. (2022) · Kidney360 · doi:10.34067/kid.0001582022 · Cited by 18 · see citing works
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection
Ros, J., Matos, I. G., & Martín-Liberal, J. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz129 · Cited by 15 · see citing works
Feng, G., Li, Q., Zhu, H., Jiang, Y., Yuan, J., Fu, Y., & Deng, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.726134 · Cited by 14 · see citing works
Immune checkpoint inhibitors in the management of malignancies in transplant recipients
Regalla, D. K. R., Williams, G. R., & Paluri, R. K. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136081 · Cited by 13 · see citing works
Joo, V., Abdelhamid, K., Noto, A., Latifyan, S., Martina, F., Daoudlarian, D., Micheli, R. D., Pruijm, M. T., Peters, S., Hullin, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47965-3 · Cited by 13 · see citing works
A novel approach to candidemia? The potential role of checkpoint inhibition
Mellinghoff, S. C., von Bergwelt‐Baildon, M., Schößer, H. A., & Cornely, O. A. (2018) · Medical Mycology · doi:10.1093/mmy/myy089 · Cited by 12 · see citing works
Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
Catalano, M., Roviello, G., Galli, I. C., Santi, R., & Nesi, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1014257 · Cited by 10 · see citing works
Bolufer, M., Soler-Majoral, J., Molina, M., Taco, O., Vila, A., & Macía, M. (2024) · Transplant International · doi:10.3389/ti.2024.13204 · Cited by 10 · see citing works
Wong, K., Shen, J., DâAmbruoso, S., Stefanoudakis, D., & Drakaki, A. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.08.002 · Cited by 10 · see citing works
Romagnoli, J., Tagliaferri, L., Acampora, A., Bianchi, V., D’Ambrosio, V., D’Aviero, A., Esposito, I., Hohaus, S., Iezzi, R., Lancellotta, V., et al. (2021) · Transplantation Reviews · doi:10.1016/j.trre.2021.100636 · Cited by 9 · see citing works
Barbir, E., Abdulmoneim, S., Dudek, A. Z., & Kukla, A. (2024) · Transplant International · doi:10.3389/ti.2024.13322 · Cited by 9 · see citing works
Alonso, F., de Francisco, Á. L. M. M., Auñón, P., García-Carro, C., García, P., Gutiérrez, E., Mcía, M., Quintana, L. F., Quiroga, B., Soler, M. J., et al. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.11.001 · Cited by 9 · see citing works
Miao, K., & Zhang, L. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00437-4 · Cited by 9 · see citing works
Corneli, P., Conforti, C., Retrosi, C., Vezzoni, R., di Meo, N., Piccolo, V., Farinazzo, E., Russo, T. P., Rizzi, G. M., Giuffrida, R., et al. (2020) · Dermatologic Therapy · doi:10.1111/dth.13250 · Cited by 9 · see citing works
Toxicités rénales des inhibiteurs des points de contrôle de l’auto-immunité
Izzedine, H., & Gueutin, V. (2019) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2019.05.006 · Cited by 8 · see citing works
Sunshine, J. C., Sosman, J. A., Shetty, A. A., & Choi, J. N. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000319 · Cited by 8 · see citing works
The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma
Hanna, D., Law, S., Merrick, S., Heptinstall, L., Bass, P., Dupont, P. J., & Sheri, A. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000651 · Cited by 8 · see citing works
Immunotherapies and renal injury
Shaikh, A. (2022) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2022.100362 · Cited by 7 · see citing works
- Authors
- Barnett, R., Barta, V. S., & Jhaveri, K. D.
- Affiliations
- Hofstra University (US)
- ORCID
- Jhaveri, Kenar D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-01-12
- Volume
- 376
- Issue
- 2
- Pages
- 191-192
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2578082697
- Cited by
- 136
- References
- 5
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 14 · 2023: 6 · 2022: 18 · 2021: 12 · 2020: 26 · 2019: 16 · 2018: 21 · 2017: 17
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- nivolumab, kidney transplantation, immune checkpoint inhibitors, graft rejection, antibody-mediated rejection, cell-mediated rejection, living related donors, renal allograft function
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Duodenal Neoplasms, Humans, Liver Neoplasms, Male, Kidney Transplantation, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
